Amgen, Inc. (NASDAQ:AMGN)

biotech

The Most Loved Biotechs of Big Hedge Funds

With such a mixed performance over the past decade, some of us wonder why hedge funds are so revered. Ditto for many of the so-called guru fund managers. Still, investors ...
Read Full Story »
biotech

Short Sellers Start to Get Nervous on Biotech

The short interest data are out for the April 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Kinder Morgan

Massive Energy Trade Highlights High-Profile Insider Selling This Week

While the volume for insider trading has dropped dramatically due to earnings reporting, some very large trades hit the tape this week. Although many insiders at major corporations are still ...
Read Full Story »
Rite Aid

3 Top Stocks to Buy That Delivered Great Earnings

While often the top firms on Wall Street take a shot and advise clients to buy stocks in front of earnings, that only works when they actually beat earnings and ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Barrick, Facebook, Halcon, Qualcomm, Synchrony, Texas Instruments and More

Stocks were indicated to take a breather on Thursday, but this week has so far been one of recovery rallying. If there is a trend that was set in stone, it has been ...
Read Full Story »
generic drugs

Amgen Earnings Point to More Froth in the Biotech Sector

Amgen Corp. (NASDAQ: AMGN) reported first-quarter 2015 earnings Tuesday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.48 on revenues of $5.03 ...
Read Full Story »
biotech

Will Amgen Earnings Shape Biotech for the Rest of 2015?

After markets close on Tuesday, Amgen Inc. (NASDAQ: AMGN) is scheduled to announce its first-quarter results. Among biotech companies Amgen is the second-largest measured by market cap, trailing only Gilead ...
Read Full Story »
Biotechnology word cloud

Short Sellers Increase Their Bets Against Biotech Stocks

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Bull and Bear

Goldman Sachs Cheapest Stocks, 6 Best Sector By Sector

If there is one firm on Wall Street that investors have been told that they want to pay attention to during analyst upgrades and downgrades, it is Goldman Sachs. The firm ...
Read Full Story »
Money background. Close-up.

Is a Big Share Buyback Coming to DaVita?

DaVita Healthcare Partners Inc. (NYSE: DVA) is in a very interesting spot. The stock is just $1.50 short of the 52-week high, while the company transitions chief financial officers, and ...
Read Full Story »
DNA

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases. A ...
Read Full Story »
Biotechnology word cloud

Short Sellers Get More Aggressive on Big Biotech

The short interest data are out for the February 27 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »